CAR-T (Chimeric Antigen Receptor T-cells) therapy genetically modifies the patient’s T-cells to attack cancers. A decision by Novartis to disband its cell and gene therapy unit has dented confidence in the field.

There are concerns about the side-effects of CAR-T, which can cause a “cytokine storm”, an extreme immune reaction in patients, with potentially lethal consequences.